nature
publishes
new
research
vir
biotechnology
demonstrating
capacity
enhanced
monoclonal
antibodies
induce
protective
adaptive
immunity
viral
infection
nasdaq
vir
data
demonstrate
potential
enhance
effector
function
monoclonal
antibodies
induce
protective
vaccinal
response
therapeutic
approach
previously
applied
treatment
oncologic
diseases
may
broader
implications
across
range
infectious
diseases
san
francisco
globe
newswire
vir
biotechnology
nasdaq
vir
today
announced
publication
preclinical
research
influenza
animal
model
highlighting
new
mechanism
enhancing
efficacy
monoclonal
antibodies
treat
viral
infection
induce
protective
response
data
demonstrate
selective
engagement
activating
fc
receptor
dendritic
cells
antiviral
monoclonal
antibodies
induced
protective
cell
adaptive
responses
paper
entitled
antibodies
elicit
immunity
viral
respiratory
infection
published
october
online
edition
nature
past
several
years
gained
better
understanding
integral
fc
mediated
effector
functions
monoclonal
antibodies
therapeutic
efficacy
models
neoplastic
infectious
inflammatory
diseases
said
jeffrey
ravetch
study
senior
author
theresa
eugene
lang
professor
head
leonard
wagner
laboratory
molecular
genetics
immunology
rockefeller
university
approaches
successfully
applied
therapeutics
resulted
improved
clinical
outcomes
variety
oncologic
diseases
present
studies
uncovered
significant
new
mechanism
antibodies
fc
region
engage
innate
immune
responses
activate
adaptive
cell
responses
thereby
stimulating
protective
immunity
research
published
nature
focuses
role
fc
domain
monoclonal
antibodies
regions
capacity
bind
immune
cells
family
receptors
fc
receptors
engineering
antibodies
modified
fc
domains
enhance
binding
specific
fc
receptors
innate
immune
cells
investigators
observed
enhanced
protective
immune
response
certain
modifications
gaalie
variants
associated
activation
dendritic
cells
well
antiviral
effector
indicating
induction
adaptive
arm
immune
system
responsible
immunity
based
research
monoclonal
antibodies
programmed
improved
effector
function
represent
potential
new
approach
design
therapeutic
antibodies
prevention
treatment
infectious
diseases
observing
learning
body
powerful
natural
defenses
discovered
maximize
capacity
antibodies
amplification
key
characteristics
may
enable
effective
treatments
viral
diseases
said
herbert
skip
virgin
study
executive
vice
president
research
chief
scientific
officer
vir
data
may
significant
implications
across
wide
range
infectious
diseases
look
forward
exploring
vaccinal
potential
antibodies
advancing
clinical
development
chronic
hepatitis
b
preclinical
study
conducted
ravetch
stylianos
bournazos
laboratory
molecular
genetics
immunology
rockefeller
university
collaboration
virgin
davide
corti
senior
vice
president
antibody
research
vir
subsidiary
humabs
biomed
sa
type
exceptional
collaborative
partnership
science
clinical
application
potential
significantly
improve
ability
address
infectious
diseases
stated
virgin
vir
currently
evaluating
several
monoclonal
antibodies
fc
engineered
include
vaccinal
mutation
gaalie
variant
vir
licensed
exclusive
rights
infectious
diseases
subcutaneously
administered
monoclonal
antibody
designed
block
entry
genotypes
hbv
hepatocytes
also
reduce
level
virions
subviral
particles
blood
engineered
extended
well
potentially
function
cell
vaccine
hbv
infected
patients
monoclonal
antibody
shown
ability
neutralize
live
virus
vitro
antibody
binds
epitope
shared
also
known
sars
indicating
epitope
highly
conserved
may
make
difficult
escape
mutants
develop
engineered
potential
enhance
lung
bioavailability
extended
function
therapeutic
prophylactic
cell
vaccine
developed
vir
partner
glaxosmithkline
plc
lse
nyse
gsk
part
broader
collaboration
research
develop
solutions
coronaviruses
including
vir
biotechnology
vir
biotechnology
immunology
company
focused
combining
immunologic
insights
technologies
treat
prevent
serious
infectious
diseases
vir
assembled
four
technology
platforms
designed
stimulate
enhance
immune
system
exploiting
critical
observations
natural
immune
processes
current
development
pipeline
consists
product
candidates
targeting
hepatitis
b
virus
influenza
human
immunodeficiency
virus
tuberculosis
information
please
visit
vir
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
potential
may
could
expect
plan
anticipate
believe
estimate
goal
intend
candidate
continuing
developing
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
vir
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
actual
results
may
differ
materially
statements
statements
contained
press
release
include
statements
regarding
ability
enhanced
fc
mediated
effector
functions
enhancing
efficacy
monoclonal
antibodies
treat
viral
infections
inducing
protective
response
animal
models
using
oncological
therapeutic
approach
enhanced
effector
function
treatment
infectious
diseases
vaccinal
potential
specifically
engineered
antibodies
treatment
chronic
hepatitis
b
statements
around
company
plans
explore
vaccinal
potential
engineered
antibodies
advances
clinical
development
treatment
chronic
hepatitis
b
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
observed
preclinical
clinical
studies
challenges
treating
chronic
hepatitis
b
neutralizing
difficulty
collaborating
companies
government
agencies
challenges
accessing
manufacturing
capacity
factors
may
cause
actual
results
differ
expressed
implied
statements
press
release
discussed
vir
filings
securities
exchange
commission
including
section
titled
risk
factors
contained
therein
except
required
law
vir
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
